来自罕见病临床研究网络(RDCRN)的数据共享经验、指导和资源

IF 2.8 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Elaine Schwendeman, Henry J. Kaminski, Adeline Vanderver, Michael Wagner, Eileen King, The RDCRN Data Use & Data Sharing Committee, Maurizio Macaluso
{"title":"来自罕见病临床研究网络(RDCRN)的数据共享经验、指导和资源","authors":"Elaine Schwendeman,&nbsp;Henry J. Kaminski,&nbsp;Adeline Vanderver,&nbsp;Michael Wagner,&nbsp;Eileen King,&nbsp;The RDCRN Data Use & Data Sharing Committee,&nbsp;Maurizio Macaluso","doi":"10.1111/cts.70340","DOIUrl":null,"url":null,"abstract":"<p>The Rare Diseases Clinical Research Network (RDCRN) comprises research consortia and other partners focused on the study of rare diseases. Its goals include sharing de-identified data with the scientific community and other stakeholders to advance rare disease research. The RDCRN Data Use &amp; Data Sharing Committee and RDCRN Data Management and Coordinating Center reviewed data sharing practices across established consortia and published literature to develop guidance documents. The Committee produced “RDCRN Suggestions for Establishing Data Sharing and Data Management Guidance for Individual Consortia”, which lays out the common elements of successful data sharing, and “Principles of Data Sharing Checklist,” which outlines the components of informed consent language, contractual language, and consortium policies that govern data sharing and use. Key principles of the guidance are: (1) informed consent language should allow data sharing while protecting participants' rights, (2) the research database should track participant's choices on how their data can be used and shared to ensure appropriate data use limitations are followed, (3) the research protocol and consortium agreements should include language stipulating that data will be shared with the consortium Administrative Core (Admin Core) for the purpose of further sharing according to NIH policies, and (4) consortia policies and agreements should emphasize the role of the Admin Core as the primary steward of the collective data and recognize its authority to further share consortium data. The RDCRN experience and learnings contribute to the advancement of Clinical and Translational Science and may help other research networks in designing data sharing policies.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 9","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70340","citationCount":"0","resultStr":"{\"title\":\"Data Sharing Experience, Guidance, and Resources From the Rare Diseases Clinical Research Network (RDCRN)\",\"authors\":\"Elaine Schwendeman,&nbsp;Henry J. Kaminski,&nbsp;Adeline Vanderver,&nbsp;Michael Wagner,&nbsp;Eileen King,&nbsp;The RDCRN Data Use & Data Sharing Committee,&nbsp;Maurizio Macaluso\",\"doi\":\"10.1111/cts.70340\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The Rare Diseases Clinical Research Network (RDCRN) comprises research consortia and other partners focused on the study of rare diseases. Its goals include sharing de-identified data with the scientific community and other stakeholders to advance rare disease research. The RDCRN Data Use &amp; Data Sharing Committee and RDCRN Data Management and Coordinating Center reviewed data sharing practices across established consortia and published literature to develop guidance documents. The Committee produced “RDCRN Suggestions for Establishing Data Sharing and Data Management Guidance for Individual Consortia”, which lays out the common elements of successful data sharing, and “Principles of Data Sharing Checklist,” which outlines the components of informed consent language, contractual language, and consortium policies that govern data sharing and use. Key principles of the guidance are: (1) informed consent language should allow data sharing while protecting participants' rights, (2) the research database should track participant's choices on how their data can be used and shared to ensure appropriate data use limitations are followed, (3) the research protocol and consortium agreements should include language stipulating that data will be shared with the consortium Administrative Core (Admin Core) for the purpose of further sharing according to NIH policies, and (4) consortia policies and agreements should emphasize the role of the Admin Core as the primary steward of the collective data and recognize its authority to further share consortium data. The RDCRN experience and learnings contribute to the advancement of Clinical and Translational Science and may help other research networks in designing data sharing policies.</p>\",\"PeriodicalId\":50610,\"journal\":{\"name\":\"Cts-Clinical and Translational Science\",\"volume\":\"18 9\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70340\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cts-Clinical and Translational Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70340\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cts-Clinical and Translational Science","FirstCategoryId":"3","ListUrlMain":"https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70340","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

罕见病临床研究网络(RDCRN)由专注于罕见病研究的研究联盟和其他合作伙伴组成。其目标包括与科学界和其他利益相关者共享去识别数据,以推进罕见病研究。RDCRN数据使用和数据共享委员会和RDCRN数据管理和协调中心审查了已建立的联盟的数据共享实践和已发表的文献,以制定指导性文件。委员会制定了“RDCRN关于为单个联盟建立数据共享和数据管理指南的建议”,列出了成功数据共享的共同要素,以及“数据共享清单原则”,概述了知情同意语言、合同语言和管理数据共享和使用的联盟政策的组成部分。该指引的主要原则如下:(1)知情同意语言应允许数据共享,同时保护参与者的权利;(2)研究数据库应跟踪参与者对如何使用和共享其数据的选择,以确保遵循适当的数据使用限制;(3)研究方案和联盟协议应包括规定数据将与联盟行政核心(Admin Core)共享的语言,以便根据NIH政策进一步共享。(4)联盟政策和协议应强调管理核心作为集体数据的主要管理者的作用,并承认其进一步共享联盟数据的权力。RDCRN的经验和学习有助于临床和转化科学的进步,并可能有助于其他研究网络设计数据共享政策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Data Sharing Experience, Guidance, and Resources From the Rare Diseases Clinical Research Network (RDCRN)

Data Sharing Experience, Guidance, and Resources From the Rare Diseases Clinical Research Network (RDCRN)

Data Sharing Experience, Guidance, and Resources From the Rare Diseases Clinical Research Network (RDCRN)

Data Sharing Experience, Guidance, and Resources From the Rare Diseases Clinical Research Network (RDCRN)

Data Sharing Experience, Guidance, and Resources From the Rare Diseases Clinical Research Network (RDCRN)

The Rare Diseases Clinical Research Network (RDCRN) comprises research consortia and other partners focused on the study of rare diseases. Its goals include sharing de-identified data with the scientific community and other stakeholders to advance rare disease research. The RDCRN Data Use & Data Sharing Committee and RDCRN Data Management and Coordinating Center reviewed data sharing practices across established consortia and published literature to develop guidance documents. The Committee produced “RDCRN Suggestions for Establishing Data Sharing and Data Management Guidance for Individual Consortia”, which lays out the common elements of successful data sharing, and “Principles of Data Sharing Checklist,” which outlines the components of informed consent language, contractual language, and consortium policies that govern data sharing and use. Key principles of the guidance are: (1) informed consent language should allow data sharing while protecting participants' rights, (2) the research database should track participant's choices on how their data can be used and shared to ensure appropriate data use limitations are followed, (3) the research protocol and consortium agreements should include language stipulating that data will be shared with the consortium Administrative Core (Admin Core) for the purpose of further sharing according to NIH policies, and (4) consortia policies and agreements should emphasize the role of the Admin Core as the primary steward of the collective data and recognize its authority to further share consortium data. The RDCRN experience and learnings contribute to the advancement of Clinical and Translational Science and may help other research networks in designing data sharing policies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cts-Clinical and Translational Science
Cts-Clinical and Translational Science 医学-医学:研究与实验
CiteScore
6.70
自引率
2.60%
发文量
234
审稿时长
6-12 weeks
期刊介绍: Clinical and Translational Science (CTS), an official journal of the American Society for Clinical Pharmacology and Therapeutics, highlights original translational medicine research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. Translational medicine is a multi-faceted discipline with a focus on translational therapeutics. In a broad sense, translational medicine bridges across the discovery, development, regulation, and utilization spectrum. Research may appear as Full Articles, Brief Reports, Commentaries, Phase Forwards (clinical trials), Reviews, or Tutorials. CTS also includes invited didactic content that covers the connections between clinical pharmacology and translational medicine. Best-in-class methodologies and best practices are also welcomed as Tutorials. These additional features provide context for research articles and facilitate understanding for a wide array of individuals interested in clinical and translational science. CTS welcomes high quality, scientifically sound, original manuscripts focused on clinical pharmacology and translational science, including animal, in vitro, in silico, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of both traditional drugs and innovative modalities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信